Core Insights - Medtronic (MDT.US) shares rose over 4% to $94.04 following the release of its Q1 fiscal year 2026 earnings report, which showed revenue of $8.6 billion, exceeding market expectations of $8.4 billion, driven primarily by growth in the cardiovascular products segment [1] - The company's adjusted earnings per share increased by 2% to $1.26, surpassing the market forecast of $1.23 [1] - Medtronic, along with peers such as Stryker (SYK.US), Boston Scientific (BSX.US), and GE HealthCare Technologies (GEHC.US), revised its tariff cost forecast downwards, now expecting a loss of $185 million compared to the previous estimate of $200 million to $350 million [1] - The company has updated its fiscal year 2026 adjusted earnings per share guidance to a range of $5.60 to $5.66, higher than the prior forecast of $5.50 to $5.60 [1]

Group 1 - Medtronic's stock price has declined for two consecutive days, totaling a drop of 3.35%, reaching a new low since July 2025, which has attracted market attention [1] - Elliott Management has become a significant shareholder in Medtronic, advocating for changes in the company's governance structure, including the addition of two independent directors and the establishment of a special committee focused on growth and operations [1] - Despite Medtronic's Q1 FY2026 revenue of $8.6 billion, which exceeded market expectations of $8.4 billion, the stock price did not respond positively, indicating that the market may have already priced in the good news [1] Group 2 - Medtronic's recent actions reflect a proactive approach to seeking transformation through governance adjustments and sustained performance growth to enhance overall competitiveness [2] - Investors should monitor the subsequent impacts of these reforms and their support for the long-term development of the company's core business [2] - The stock price fluctuations of Medtronic illustrate the market's digestion process regarding the company's governance changes and performance [2]

Group 1 - Medtronic reported Q1 FY2026 revenue of $8.6 billion, exceeding market expectations of $8.4 billion, driven by growth in the cardiovascular products segment, with cardiac ablation product revenue increasing nearly 50% [1] - Adjusted EPS grew by 2% to $1.26, surpassing the market forecast of $1.23 [1] - Medtronic lowered its tariff cost forecast to $185 million from a previous estimate of $200 million to $350 million [1] Group 2 - Medtronic raised its FY2026 adjusted EPS guidance to a range of $5.60 to $5.66, up from the prior forecast of $5.50 to $5.60 [1] - The company continues to expect an organic revenue growth rate of 5% for FY2026 [1] - Following the investment from Elliott Investment Management, Medtronic plans to expand its board and appoint experienced individuals in the medical technology field as independent directors [2]